CD30 in Normal and Neoplastic Cells

Overview of attention for article published in Clinical Immunology, February 1999

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

policy: 1 policy source
patent: 14 patents

guideline: 1 clinical guideline source

Readers on

mendeley: 39 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Adcetris for systemic Anaplastic Large Cell Lymphoma - Details - Brentuximab (Adcetris) for sALCL - Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 15 Mar 2013

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Adcetris for Hodgkin Lymphoma - Details - Brentuximab (Adcetris) for Hodgkin Lymphoma - Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 14 Mar 2013

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.